PRKCDBP Antibody (8D3): sc-293329

PRKCDBP Antibody (8D3) is a mouse monoclonal IgG1 kappa light chain antibody that detects the PRKCDBP protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-PRKCDBP antibody (8D3) is available as the non-conjugated format. PRKCDBP protein, also known as protein kinase C, delta binding protein, SRBC, HSRBC, or cavin-3, consists of 261 amino acids and belongs to the STICK (substrates that interact with C-kinase) superfamily of PKC-binding proteins, exhibiting strong expression in mammary and epithelial cells. PRKCDBP plays a crucial role in cellular signaling by interacting with PRKCD and phosphatidylserine, which enhances the stability of binding between protein kinase C and its binding partners, thereby facilitating important signaling pathways. Notably, PRKCDBP is recognized as a novel tumor suppressor, as PRKCDBP is down-regulated in various cancer cell lines, including those from breast and lung cancers, and PRKCDBP function can be compromised through methylation. Additionally, PRKCDBP may contribute to immune potentiation and act as a caveolin adapter, regulating caveolae function, which is vital for cellular communication and transport. PRKCDBP phosphorylation is stimulated by NK-1R (neurokinin 1 receptor), a G protein-coupled receptor implicated in human glioblastomas, further underscoring PRKCDBP significance in cancer biology and potential therapeutic targets.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PRKCDBP Antibody (8D3) References:

1. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.  |  Xu, XL., et al. 2001. Cancer Res. 61: 7943-9. PMID: 11691816
2. Differential regulation of the protein tyrosine kinase activity following interleukin-2 (IL-2), interferron gamma (IFN-gamma) and SRBC administration in brain tumor-induced conditions: SRBC acting as a dual potentiator in regulating the cytokine profile.  |  Bhattacharjee, M., et al. 2004. Cancer Biol Ther. 3: 755-60. PMID: 15197346
3. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.  |  Zöchbauer-Müller, S., et al. 2005. Oncogene. 24: 6249-55. PMID: 15940253
4. Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.  |  Yamaguchi, K., et al. 2005. Cancer Chemother Pharmacol. 56: 585-93. PMID: 16012865
5. Microarray analysis of promoter methylation in lung cancers.  |  Fukasawa, M., et al. 2006. J Hum Genet. 51: 368-374. PMID: 16435073
6. Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.  |  Lee, JH., et al. 2008. Int J Cancer. 122: 1573-84. PMID: 18059034
7. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function.  |  McMahon, KA., et al. 2009. EMBO J. 28: 1001-15. PMID: 19262564
8. A microarray-based DNA methylation study of glioblastoma multiforme.  |  Martinez, R., et al. 2009. Epigenetics. 4: 255-64. PMID: 19550145
9. A protein kinase Cdelta-binding protein SRBC whose expression is induced by serum starvation.  |  Izumi, Y., et al. 1997. J Biol Chem. 272: 7381-9. PMID: 9054438